Generic placeholder image

Current Vascular Pharmacology

Editor-in-Chief

ISSN (Print): 1570-1611
ISSN (Online): 1875-6212

Editorial

Thyroid Status and Vascular Risk: An Update

Author(s): Emir Muzurović*, Sanja Borozan, Snežana Vujošević and Mark Gurnell

Volume 20, Issue 6, 2022

Published on: 17 October, 2022

Page: [460 - 462] Pages: 3

DOI: 10.2174/1570161120666221004144414

conference banner
[1]
Stamatouli A, Bedoya P, Yavuz S. Hypothyroidism: Cardiovascular endpoints of thyroid hormone replacement. Front Endocrinol (Lausanne) 2020; 10: 888.
[http://dx.doi.org/10.3389/fendo.2019.00888] [PMID: 31998229]
[2]
Jabbar A, Pingitore A, Pearce SHS, Zaman A, Iervasi G, Razvi S. Thyroid hormones and cardiovascular disease. Nat Rev Cardiol 2017; 14(1): 39-55.
[http://dx.doi.org/10.1038/nrcardio.2016.174] [PMID: 27811932]
[3]
Gluvic ZM, Zafirovic SS, Obradovic MM, Sudar-Milovanovic EM, Rizzo M, Isenovic ER. Hypothyroidism and risk of cardiovascular dis-ease. Curr Pharm Des 2022; 28(25): 2065-72.
[http://dx.doi.org/10.2174/1381612828666220620160516] [PMID: 35726428]
[4]
Evron JM, Hummel SL, Reyes-Gastelum D, Haymart MR, Banerjee M, Papaleontiou M. Association of thyroid hormone treatment intensity with cardiovascular mortality among US veterans. JAMA Netw Open 2022; 5(5): e2211863.
[http://dx.doi.org/10.1001/jamanetworkopen.2022.11863] [PMID: 35552725]
[5]
Brent GA. Mechanisms of thyroid hormone action. J Clin Invest 2012; 122(9): 3035-43.
[http://dx.doi.org/10.1172/JCI60047] [PMID: 22945636]
[6]
Bernardi S, Grillo A, Antonello RM, et al. Meta-analysis on the association between thyroid hormone disorders and arterial stiffness. J Endocr Soc 2022; 6(4): bvac016.
[http://dx.doi.org/10.1210/jendso/bvac016] [PMID: 35284772]
[7]
Tzotzas T, Krassas GE, Konstantinidis T, Bougoulia M. Changes in lipoprotein(a) levels in overt and subclinical hypothyroidism before and during treatment. Thyroid 2000; 10(9): 803-8.
[http://dx.doi.org/10.1089/thy.2000.10.803] [PMID: 11041458]
[8]
Razvi S, Ingoe L, Keeka G, Oates C, McMillan C, Weaver JU. The beneficial effect of L-thyroxine on cardiovascular risk factors, endotheli-al function, and quality of life in subclinical hypothyroidism: Randomized, crossover trial. J Clin Endocrinol Metab 2007; 92(5): 1715-23.
[http://dx.doi.org/10.1210/jc.2006-1869] [PMID: 17299073]
[9]
Wang X, Wang H, Li Q, et al. Effect of levothyroxine supplementation on the cardiac morphology and function in patients with subclinical hypothyroidism: A systematic review and meta-analysis. J Clin Endocrinol Metab 2022; 107(9): 2674-83.
[http://dx.doi.org/10.1210/clinem/dgac417] [PMID: 35810404]
[10]
Peng CCH, Huang HK, Wu BBC, Chang RHE, Tu YK, Munir KM. Association of thyroid hormone therapy with mortality in subclinical hypothyroidism: A systematic review and meta-analysis. J Clin Endocrinol Metab 2021; 106(1): 292-303.
[http://dx.doi.org/10.1210/clinem/dgaa777] [PMID: 33107557]
[11]
Brandt F, Green A, Hegedüs L, Brix TH. A critical review and meta-analysis of the association between overt hyperthyroidism and mortali-ty. Eur J Endocrinol 2011; 165(4): 491-7.
[http://dx.doi.org/10.1530/EJE-11-0299] [PMID: 21724839]
[12]
Frost L, Vestergaard P, Mosekilde L. Hyperthyroidism and risk of atrial fibrillation or flutter: A population-based study. Arch Intern Med 2004; 164(15): 1675-8.
[http://dx.doi.org/10.1001/archinte.164.15.1675] [PMID: 15302638]
[13]
Cappola AR, Desai AS, Medici M, et al. Thyroid and cardiovascular disease. Circulation 2019; 139(25): 2892-909.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.118.036859] [PMID: 31081673]

© 2024 Bentham Science Publishers | Privacy Policy